154 related articles for article (PubMed ID: 18604246)
1. Complementing mutations in core binding factor leukemias: from mouse models to clinical applications.
Müller AM; Duque J; Shizuru JA; Lübbert M
Oncogene; 2008 Oct; 27(44):5759-73. PubMed ID: 18604246
[TBL] [Abstract][Full Text] [Related]
2. Core binding factor acute myeloid leukaemia and c-KIT mutations.
Riera L; Marmont F; Toppino D; Frairia C; Sismondi F; Audisio E; Di Bello C; D'Ardia S; Di Celle PF; Messa E; Inghirami G; Vitolo U; Pich A
Oncol Rep; 2013 May; 29(5):1867-72. PubMed ID: 23467883
[TBL] [Abstract][Full Text] [Related]
3. Prognostic impact of c-KIT mutations in core binding factor acute myeloid leukemia.
Park SH; Chi HS; Min SK; Park BG; Jang S; Park CJ
Leuk Res; 2011 Oct; 35(10):1376-83. PubMed ID: 21715005
[TBL] [Abstract][Full Text] [Related]
4. A new D816 c-KIT gene mutation in refractory AML1-ETO leukemia.
Lasa A; Carricondo MT; Carnicer MJ; Perea G; Aventín A; Nomdedeu JF
Haematologica; 2006 Sep; 91(9):1283-4. PubMed ID: 16956837
[TBL] [Abstract][Full Text] [Related]
5. Core-binding factor acute myeloid leukemia.
Sangle NA; Perkins SL
Arch Pathol Lab Med; 2011 Nov; 135(11):1504-9. PubMed ID: 22032582
[TBL] [Abstract][Full Text] [Related]
6. KIT mutations confer a distinct gene expression signature in core binding factor leukaemia.
Lück SC; Russ AC; Du J; Gaidzik V; Schlenk RF; Pollack JR; Döhner K; Döhner H; Bullinger L
Br J Haematol; 2010 Mar; 148(6):925-37. PubMed ID: 20064158
[TBL] [Abstract][Full Text] [Related]
7. Clinical significance of the most common chromosome translocations in adult acute myeloid leukemia.
Mrózek K; Bloomfield CD
J Natl Cancer Inst Monogr; 2008; (39):52-7. PubMed ID: 18648004
[TBL] [Abstract][Full Text] [Related]
8. Core binding factor acute myeloid leukemia.
Paschka P
Semin Oncol; 2008 Aug; 35(4):410-7. PubMed ID: 18692691
[TBL] [Abstract][Full Text] [Related]
9. KIT and FLT3 receptor tyrosine kinase mutations in acute myeloid leukemia with favorable cytogenetics: two novel mutations and selective occurrence in leukemia subtypes and age groups.
Sritana N; Auewarakul CU
Exp Mol Pathol; 2008 Dec; 85(3):227-31. PubMed ID: 18977345
[TBL] [Abstract][Full Text] [Related]
10. Immunophenotypic profile predictive of KIT activating mutations in AML1-ETO leukemia.
De J; Zanjani R; Hibbard M; Davis BH
Am J Clin Pathol; 2007 Oct; 128(4):550-7. PubMed ID: 17875504
[TBL] [Abstract][Full Text] [Related]
11. Diagnosis and management of core-binding factor leukemias.
Seiter K
Curr Hematol Rep; 2003 Jan; 2(1):78-85. PubMed ID: 12901158
[TBL] [Abstract][Full Text] [Related]
12. Additional chromosomal abnormalities in core-binding factor acute myeloid leukemia.
Hsiao HH; Liu YC; Wang HC; Tsai YF; Wu CH; Cho SF; Hsu JF; Huang CT; Hsiao SY; Lee CP; Chang CS; Lin SF; Liu TC
Genet Mol Res; 2015 Dec; 14(4):17028-33. PubMed ID: 26681050
[TBL] [Abstract][Full Text] [Related]
13. Common gene expression signatures in t(8;21)- and inv(16)-acute myeloid leukaemia.
Ichikawa H; Tanabe K; Mizushima H; Hayashi Y; Mizutani S; Ishii E; Hongo T; Kikuchi A; Satake M
Br J Haematol; 2006 Nov; 135(3):336-47. PubMed ID: 16989659
[TBL] [Abstract][Full Text] [Related]
14. Adverse prognostic significance of KIT mutations in adult acute myeloid leukemia with inv(16) and t(8;21): a Cancer and Leukemia Group B Study.
Paschka P; Marcucci G; Ruppert AS; Mrózek K; Chen H; Kittles RA; Vukosavljevic T; Perrotti D; Vardiman JW; Carroll AJ; Kolitz JE; Larson RA; Bloomfield CD;
J Clin Oncol; 2006 Aug; 24(24):3904-11. PubMed ID: 16921041
[TBL] [Abstract][Full Text] [Related]
15. Review: genetic models of acute myeloid leukaemia.
McCormack E; Bruserud O; Gjertsen BT
Oncogene; 2008 Jun; 27(27):3765-79. PubMed ID: 18264136
[TBL] [Abstract][Full Text] [Related]
16. Comprehensive analysis of cooperative gene mutations between class I and class II in de novo acute myeloid leukemia.
Ishikawa Y; Kiyoi H; Tsujimura A; Miyawaki S; Miyazaki Y; Kuriyama K; Tomonaga M; Naoe T
Eur J Haematol; 2009 Aug; 83(2):90-8. PubMed ID: 19309322
[TBL] [Abstract][Full Text] [Related]
17. Pathogenesis of acute myeloid leukaemia and inv(16)(p13;q22): a paradigm for understanding leukaemogenesis?
Reilly JT
Br J Haematol; 2005 Jan; 128(1):18-34. PubMed ID: 15606546
[TBL] [Abstract][Full Text] [Related]
18. Core binding factor acute myeloid leukemia (CBF-AML): is high-dose Ara-C (HDAC) consolidation as effective as you think?
Dombret H; Preudhomme C; Boissel N
Curr Opin Hematol; 2009 Mar; 16(2):92-7. PubMed ID: 19468270
[TBL] [Abstract][Full Text] [Related]
19. Gene-expression profiling identifies distinct subclasses of core binding factor acute myeloid leukemia.
Bullinger L; Rücker FG; Kurz S; Du J; Scholl C; Sander S; Corbacioglu A; Lottaz C; Krauter J; Fröhling S; Ganser A; Schlenk RF; Döhner K; Pollack JR; Döhner H
Blood; 2007 Aug; 110(4):1291-300. PubMed ID: 17485551
[TBL] [Abstract][Full Text] [Related]
20. Acceleration of G(1) cooperates with core binding factor beta-smooth muscle myosin heavy chain to induce acute leukemia in mice.
Yang Y; Wang W; Cleaves R; Zahurak M; Cheng L; Civin CI; Friedman AD
Cancer Res; 2002 Apr; 62(8):2232-5. PubMed ID: 11956074
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
